AdaptVac is a joint-venture between ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines.
AdaptVac has raised $12.4M in total funding. The most recent round was Grant. The last funding was announced in June 2025.
AdaptVac's investors include Horizon Europe, Coalition for Epidemic Preparedness Innovations, Innovation Fund Denmark.
AdaptVac is headquartered in Hørsholm, Denmark.
AdaptVac is a joint-venture between ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines.
AdaptVac is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AdaptVac — Funding & Investors." VCBacked, June 19, 2025, https://www.vcbacked.co/company/adaptvac. Accessed October 1, 2026.
VCBacked. (2025). AdaptVac — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/adaptvac
{{cite web |title=AdaptVac — Funding & Investors |url=https://www.vcbacked.co/company/adaptvac |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated